PMID- 28624136
OWN - NLM
STAT- MEDLINE
DCOM- 20180514
LR  - 20180622
IS  - 1873-2496 (Electronic)
IS  - 1078-1439 (Linking)
VI  - 35
IP  - 9
DP  - 2017 Sep
TI  - Effect of ABO blood type on the outcomes of patients with metastatic renal cell 
      carcinoma treated with first-line tyrosine kinase inhibitors.
PG  - 540.e7-540.e12
LID - S1078-1439(17)30162-X [pii]
LID - 10.1016/j.urolonc.2017.04.004 [doi]
AB  - OBJECTIVES: To assess the effect of blood type on survival outcomes and adverse 
      events (AEs) in patients treated with tyrosine kinase inhibitors (TKIs) for 
      metastatic renal cell carcinoma (mRCC). MATERIALS AND METHODS: Patients who 
      received TKIs as first-line therapy for mRCC between 2008 and 2015 at our 
      hospital were included in the study (n = 136). Patients were divided into 2 
      groups based on their blood type as O and non-O. Survival outcomes and AEs were 
      compared according to blood type. Cox regression models were used for univariate 
      and multivariate survival analyses. RESULTS: Of the 136 patients, 34 (25%) and 
      102 (75%) had O and non-O blood types, respectively. Blood type O was associated 
      with an increased number of disease sites. There were no differences between the 
      2 groups with respect to other baseline characteristics. The progression-free 
      survival in patients with O and non-O blood types was 12.1 and 11.6 months, 
      respectively; the overall survival was 34.4 and 24.8 months, respectively. On 
      univariate and multivariate analyses, the ABO blood type was not a significant 
      prognostic factor for progression-free survival or overall survival. Furthermore, 
      the incidences of serious AEs were similar in the 2 blood groups. CONCLUSIONS: 
      ABO blood type was not associated with survival outcomes or incidences of serious 
      AEs in mRCC patients treated with TKIs. However, blood type O may be associated 
      with an increased number of disease sites.
CI  - Copyright (c) 2017. Published by Elsevier Inc.
FAU - Omae, Kenji
AU  - Omae K
AD  - Department of Healthcare Epidemiology, Kyoto University School of Public Health, 
      Kyoto, Japan; Fukushima Medical University, Center for Innovative Research for 
      Communities and Clinical Excellence, Fukushima City, Fukushima, Japan; Department 
      of Urology, Tokyo Women׳s Medical University, Tokyo, Japan.
FAU - Fukuma, Shingo
AU  - Fukuma S
AD  - Department of Healthcare Epidemiology, Kyoto University School of Public Health, 
      Kyoto, Japan; Fukushima Medical University, Center for Innovative Research for 
      Communities and Clinical Excellence, Fukushima City, Fukushima, Japan.
FAU - Ikenoue, Tatsuyoshi
AU  - Ikenoue T
AD  - Department of Healthcare Epidemiology, Kyoto University School of Public Health, 
      Kyoto, Japan.
FAU - Kondo, Tsunenori
AU  - Kondo T
AD  - Department of Urology, Tokyo Women׳s Medical University, Tokyo, Japan.
FAU - Takagi, Toshio
AU  - Takagi T
AD  - Department of Urology, Tokyo Women׳s Medical University, Tokyo, Japan.
FAU - Ishihara, Hiroki
AU  - Ishihara H
AD  - Department of Urology, Tokyo Women׳s Medical University, Tokyo, Japan.
FAU - Tanabe, Kazunari
AU  - Tanabe K
AD  - Department of Urology, Tokyo Women׳s Medical University, Tokyo, Japan. Electronic 
      address: tanabe@kc.twmu.ac.jp.
FAU - Fukuhara, Shunichi
AU  - Fukuhara S
AD  - Department of Healthcare Epidemiology, Kyoto University School of Public Health, 
      Kyoto, Japan; Fukushima Medical University, Center for Innovative Research for 
      Communities and Clinical Excellence, Fukushima City, Fukushima, Japan.
LA  - eng
PT  - Journal Article
DEP - 20170616
PL  - United States
TA  - Urol Oncol
JT  - Urologic oncology
JID - 9805460
RN  - 0 (ABO Blood-Group System)
RN  - 0 (Protein Kinase Inhibitors)
SB  - IM
MH  - ABO Blood-Group System/*physiology
MH  - Carcinoma, Renal Cell/*blood/drug therapy/mortality/pathology
MH  - Female
MH  - Humans
MH  - Kidney Neoplasms/*blood/drug therapy/mortality/pathology
MH  - Male
MH  - Middle Aged
MH  - Protein Kinase Inhibitors/*therapeutic use
MH  - Survival Analysis
MH  - Treatment Outcome
OTO - NOTNLM
OT  - ABO blood group system
OT  - Adverse drug event
OT  - Renal cell carcinoma
OT  - Survival
OT  - Targeted molecular therapy
OT  - Treatment outcome
EDAT- 2017/06/19 06:00
MHDA- 2018/05/15 06:00
CRDT- 2017/06/19 06:00
PHST- 2017/02/10 00:00 [received]
PHST- 2017/03/29 00:00 [revised]
PHST- 2017/04/05 00:00 [accepted]
PHST- 2017/06/19 06:00 [pubmed]
PHST- 2018/05/15 06:00 [medline]
PHST- 2017/06/19 06:00 [entrez]
AID - S1078-1439(17)30162-X [pii]
AID - 10.1016/j.urolonc.2017.04.004 [doi]
PST - ppublish
SO  - Urol Oncol. 2017 Sep;35(9):540.e7-540.e12. doi: 10.1016/j.urolonc.2017.04.004. 
      Epub 2017 Jun 16.